Nexalis Ends LFO Facility, Replaces 38 Million Options With 15 Million
NX1: $0.009 +0.00% · MC: $2M
Nexalis Therapeutics says its LFO funding facility has been terminated by mutual agreement, with no repayment due and the lender’s security released; 38 million existing options have lapsed and the company proposes issuing 15 million replacement options to settle funding received. September-quarter cash fell to approximately $371,000 from $790,000 at the previous quarter-end, while the company says it is working to arrange forward funding against its research tax incentive and is seeking other funding for clinical trials.

Comments